跳至主要内容
临床试验/NCT05552040
NCT05552040已完成不适用

Adaptation and Effectiveness of START NOW in the Treatment of Opioid Addicted Individuals Enrolled in Outpatient Based Opioid Treatment

Carilion Clinic2 个研究点 分布在 1 个国家目标入组 141 人开始时间: 2018年10月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
141
试验地点
2
主要终点
Retention in treatment by group attendance

研究概览

简要总结

This investigation involves a partially randomized clinical trial examining the effectiveness of combining buprenorphine/naloxone MAT with START NOW, a skills-based psychosocial intervention modified specifically for the ambulatory substance use disorder (SUD) patient population. START NOW is an integrated evidence-informed model based on an adapted form of dialectical behavior therapy (DBT), a type of cognitive behavior therapy (CBT) with promising indications for treating SUD as it targets impulsive and self-destructive behaviors. Furthermore, START NOW combines CBT, the most widely used evidence-based psychosocial intervention for treating mental disorders, with motivational interviewing, which in clinical trials has been shown to be an effective technique for engaging patients with SUD. In addition to tracking clinical outcomes such as abstinence rates through weekly urine drug screens, this investigation will use: clinician assessments of disease severity, researcher-evaluated tests of delayed discounting (DD) and demand tasks, and self-report surveys assessing impulsivity, aggression, interpersonal skills, and other measures to capture the patients' sense of progress in treatment in regards to their substance use, health, lifestyle, and community. By using DD and functional magnetic resonance imaging (fMRI), the identification of the neural correlates of START NOW treatment response will begin to elucidate the mechanisms of START NOW's effects and more. This investigation's outcome measures may not only compare the effectiveness between START NOW and treatment-as-usual (TAU), but also provide a more realistic, holistic view of patients and their well-being throughout the recovery process.

DD will be performed by both START NOW group members and TAU group members at their group therapy meetings as per protocol. Additionally, START NOW group members randomized and consented to have an fMRI will also perform DD before the scan is initiated.

详细描述

There is an unmet need for implementing a clinically superior behavioral therapy intervention for medication-assisted treatment of opioid use disorder.

One strategy for fighting the opioid epidemic is to improve treatment and detoxification programs. In the United States, the Drug Addiction Treatment Act of 2000 requires that physicians combine medication-assisted treatment (MAT) with a behavioral intervention. However, there is no clear evidence regarding what form of therapy is most effective when coupled with MAT for opioid use disorder (OUD) management.

This investigation will explore the impact of a novel skills-based psychosocial intervention called START NOW, which has been modified for the substance use disorder (SUD) patient population. The promising therapeutic potential of START NOW is evident in the growing data affirming the program's utility and the psychosocial techniques with substantial supportive evidence incorporated into the program. This investigation will attempt to prove through a number of clinical and behavioral parameters how START NOW with MAT may be an effective treatment program for patients undergoing OUD treatment.

START NOW is an evidence-informed psychotherapy composed of a total of 32-skills-based-sessions, originally designed for inmates in correctional systems. A previous study of incarcerated individuals found that for each additional session of START NOW completed, a 5% reduction in the incident rate of disciplinary reports was noted. In fact, individuals with a higher overall security risk score also had a greater reduction in the number of disciplinary reports with more sessions attended, suggesting that START NOW is an effective behavioral intervention for those who need it most. A follow-up study on these same participants concluded that START NOW appears to have a beneficial clinical effect with each session completed being associated with a 5% decrease in subsequent psychiatric hospital days. Evidence continues to build in support for START NOW as a behavioral intervention as its implementation continues to grow. For example, START NOW is currently being used in correctional facilities in more than 10 states in the US. Using a randomized, controlled trial in Europe, investigators are evaluating START NOW's ability to enhance psychosocial adjustment and well-being and to reduce oppositional and aggressive behavior in 128 institutionalized female adolescents diagnosed with oppositional defiant disorder and/or conduct disorder.

Investigators hypothesize that OUD patients who complete START NOW group therapy will show a statistically greater reduction in impulsivity, delay discounting, and illicit drug use compared to the OUD patients who complete the treatment-as-usual (TAU) because of START NOW's integrated model of care. For example, START NOW combines CBT, the most widely used evidence-based psychosocial intervention for treating mental disorders, with motivational interviewing, which in clinical trials has been shown to be an effective conjunction intervention for SUD. START NOW exercises psychosocial techniques similar to dialectical behavior therapy (DBT), a type of cognitive behavior therapy (CBT) with promising indications for treating SUD because it targets impulsive and self-destructive behaviors. A currently unpublished pilot study using START NOW in an office-based outpatient treatment setting with OUD yielded patient satisfaction data and detailed feedback; this data is being used to guide the modification process of START NOW's materials and delivery so that START NOW is more culturally sensitive and appropriate for the SUD patient population. This proposed investigation will use the revised START NOW participant workbooks and real-life exercises adapted specifically for SUD.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
Single (Outcomes Assessor)

盲法说明

Statistical analysis completed by Virginia Tech Department of Statistics faculty and graduate students who were all blinded with respect to group assignment.

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years or older with OUD diagnosis participating in OBOT

排除标准

  • Imminent suicide risk at investigator discretion
  • Unable to commit to participation in the planned 32 session regimen
  • Unmanaged psychiatric illness that would interfere in study participation, as determined by investigator
  • Pregnant patients with OUD [for the imaging study ONLY]

结局指标

主要结局

Retention in treatment by group attendance

时间窗: 32 -52 weeks

Translates to # groups attended (max 32)

Retention in treatment by time in study

时间窗: 32 -52 weeks

Weeks from consent to last group attended

Intensity of treatment

时间窗: 32 -52 weeks

total number-of-groups-attended divided by number of weeks from consent to last group attended

Drug use based on drug screen results

时间窗: 32-52 weeks

Drug use during trial period was determined by drug screens, which were collected weekly or monthly based on clinician preference throughout the entire 8-month investigation for each participant

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Robert L Trestman

Professor and Chair, Department of Psychiatry and Behavioral Medicine

Carilion Clinic

研究点 (2)

Loading locations...

相似试验